Sentiment-Signal
21,0
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 31.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | set forth by specific reference in such filling. Item 5.02 Departure of Directors or Certain Officers; Election of Direc |
| 18.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tive Officers The information set forth in Item 5.02 of this Current Report on Form 8-K under the heading “Appointment |
| 25.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nancial or other obligations under the Agreement. Item 5.02. Departure of Directors or Certain Officers; Election of Dir |
| 29.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | eference. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Of |
| 30.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | s a result of, or associated with, these actions. Item 5.02. Departure of Directors or Certain Officers; Election of Dir |
| 13.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
| 21.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
Stammdaten
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Unternehmen & Branche
| Name | CRESCENT BIOPHARMA, INC. |
|---|---|
| Ticker | CBIO |
| CIK | 0001253689 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 572,1 Mio. USD |
| Beta | 1,03 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 10,844,000 | -153,942,000 | 240,293,000 | 203,012,000 | |
| 2025-09-30 | 10-Q | -24,607,000 | 138,269,000 | 116,641,000 | ||
| 2025-06-30 | 10-Q | -21,790,000 | 157,433,000 | 139,254,000 | ||
| 2025-03-31 | 10-Q | -15,148,000 | 5,992,180 | -30,161,000 | ||
| 2024-12-31 | 10-K | 0 | -17,867,000 | -0.59 | 35,617,000 | -15,479,000 |
| 2024-09-30 | 10-Q | -2,631,000 | -0.15 | 15,698,141 | -1,302,000 | |
| 2024-06-30 | 10-Q | -10,095,406 | -0.16 | 24,418,819 | 20,062,503 | |
| 2024-03-31 | 10-Q | -10,736,667 | -0.04 | 34,204,913 | 28,910,712 | |
| 2023-12-31 | 10-K | -36,899,420 | -0.58 | 45,316,475 | 38,414,401 | |
| 2023-09-30 | 10-Q | -9,202,518 | -0.14 | 53,200,684 | 46,547,671 | |
| 2023-06-30 | 10-Q | -8,258,912 | -0.13 | 61,821,513 | 54,800,736 | |
| 2023-03-31 | 10-Q | -10,359,350 | -0.17 | 68,921,654 | 62,181,446 | |
| 2022-12-31 | 10-K | -46,688,802 | -0.89 | 51,810,589 | 42,929,837 | |
| 2022-09-30 | 10-Q | -8,523,839 | -0.16 | 55,961,447 | 48,117,583 | |
| 2022-06-30 | 10-Q | -13,267,567 | -0.25 | 65,044,021 | 55,727,443 | |
| 2022-03-31 | 10-Q | -14,653,041 | -0.28 | 81,464,771 | 68,031,252 | |
| 2021-12-31 | 10-K | -63,427,437 | -1.23 | 94,346,648 | 81,603,651 | |
| 2021-09-30 | 10-Q | -17,332,321 | -0.34 | 107,944,903 | 96,565,748 | |
| 2021-06-30 | 10-Q | -14,399,261 | -0.28 | 124,378,679 | 112,286,420 | |
| 2021-03-31 | 10-Q | -14,274,059 | -0.28 | 138,019,903 | 125,123,520 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-04 | Fairmount Funds Management LLC | Director, 10% Owner | Open Market Purchase | 1,360,000 | 13.41 | 18,237,600.00 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.